For decades, countless individuals have lived in a state of constant self-doubt, wondering if they might have Polycystic Ovary Syndrome (PCOS). There have definitely been times I’ve questioned myself, too. PCOS has had a long, frustrating journey in the women’s health sphere, as its symptoms are frequently ambiguous with information from online searches or healthcare providers who may lack the specialized training required to recognize the vast clinical spectrum that PCOS is. As a result, PCOS remains one of the most underdiagnosed health conditions in the world, affecting an estimated 70% of individuals who remain entirely unaware that they have it [1].
In 2026, a global consensus officially initiated a transition away from the name “Polycystic Ovary Syndrome” to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The original name has been misleading because not every individual with the condition actually develops cysts on their ovaries. In the past, a provider who conducted ultrasounds to look for ovarian cysts may have ruled out PCOS because no cysts were visible. PMOS acknowledges that this is not a localized reproductive condition but is a complex, multi-systemic condition that effects reproductive, endocrine, and metabolic hormones [2-3].
Because PMOS impacts the body on a metabolic level, its signs can vary wildly from person to person. Individuals navigating the condition often experience menstrual irregularities, such as infrequent, unpredictable, or completely absent periods, alongside metabolic shifts like insulin resistance, unexplained weight gain, and marked difficulty losing weight. Elevated testosterone levels are a hallmark feature of the PMOS and may manifest physically as severe acne, male-pattern hair thinning, or hirsutism, which causes excess hair growth on the face and body. While the presence of physical cysts is no longer a strict requirement for diagnosis under the new frame, many individuals still exhibit ovarian changes, including enlarged ovaries surrounded by small, fluid-filled follicles [2-4].
Another major driving force being the 2026 decision to rename the condition as it finally integrates the cognitive and neuroendocrine changes that PMOS brings. Many individuals with PMOS report feelings of mental fatigue, difficulty concentrating, or “brain fog.” Metabolically, PMOS alters how the body processes glucose. Fluctuations in blood sugar can deprive brain cells of a steady energy supply, leading to absent focus, forgetfulness, and/or acute energy crashes. PMOS is also characterized by low-grade systemic inflammation, which can affect the blood-brain barrier and influence neuroinflammation, impacting how fast one can cognitively process information and maintain mental clarity [3-5].
A couple months ago, we discussed the hypothalamic-pituitary-ovarian (HPO) axis that produces Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), estrogen, and progesterone. We have our cycle group chat where all of these hormones communicate in tandem but then enters the angry friend, testosterone, blowing up the group chat with rude and unwanted messages. Testosterone has always been in the group chat. Progesterone and estrogen know how to get testosterone to relax when it’s just him. The issue only arises when testosterone keeps adding more and more of his friends that bring the same rude vibe to the group chat. Elevated testosterone contributes to anxiety and irritability. As a result, the disrupted group chat becomes the disrupted cycle. Fluctuations in luteinizing hormone (LH), estrogen, and progesterone do not follow normal cyclic patterns. This irregularity directly impacts mood-regulating neurotransmitters in the brain, like serotonin and dopamine [3-5].
Because PMOS as a condition has been misunderstood for so long, advocacy and self-education are our best tools: being vigilant allows you to take control of your own metabolic health and empowers you to support the people in your life who may still be suffering without a proper diagnosis.
References
- Polycystic ovary syndrome. (2025). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome.
- Tewari, S., Khalua, R. K., & Parida, S. (2026). Redefining Polycystic Ovary Syndrome (PCOS) as Polyendocrine Metabolic Ovarian Syndrome (PMOS): Implications for Diagnosis, Pathophysiology and Clinical Management. International Journal of Gynecology Sciences, 8(1), 17–25. https://doi.org/10.33545/26648393.2026.v8.i1a.55.
- Chan, J. L., Masini, I., & Pisarska, M. D. (2026). Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): Current and future trends. The Journal of Clinical Investigation, 136(12). https://doi.org/10.1172/JCI202824.
- Kordowitzki, P., & Teede, H. (2026). Polyendocrine metabolic ovarian syndrome—A new name for an old problem. Nature Metabolism, 1–3. https://doi.org/10.1038/s42255-026-01552-6.
- Tewari, S., Pramanik, P., Patra, T., & Mk, M. (2026). From Reproductive Disorder to Metabolic Syndrome: The Evolution of Polycystic Ovary Syndrome (PCOS) into Polyendocrine Metabolic Ovarian Syndrome (PMOS). Journal of Pharmacognosy and Phytochemistry, 15(3), 329–337. https://doi.org/10.22271/phyto.2026.v15.i3c.15891.
